Chegg Stock Tanks As Students Turn To ChatGPT: What’s Going On?

Chegg Inc (NYSE: CHGG) shares are plunging Tuesday after the company reported a decline in subscription services subscribers and issued guidance below analyst estimates as stud

Chegg Inc (NYSE:CHGG) shares are plunging Tuesday after the company reported a decline in subscription services subscribers and issued guidance below analyst estimates as students turn to AI.

  • Q1 Revenue: $187.6 million beats estimates of $185.18 million
  • Q1 EPS: 27 cents beats estimates of 26 cents

Revenues fell 7% year-over-year. Subscription services revenues were down 3%. Subscription services subscribers decreased 5% year-over-year to 5.1 million, driven by a spike in students opting to use Microsoft Corp (NASDAQ:MSFT)-backed ChatGPT instead of Chegg services.

“As artificial intelligence technology continues to evolve at a rapid pace, we are embracing it aggressively and prioritizing our investments to meet this opportunity,” said Dan Rosensweig, president and CEO of Chegg.

“In the first part of the year, we saw no noticeable impact from ChatGPT on our new account growth and we were meeting expectations on new sign-ups. However, since March we saw a significant spike in student interest in ChatGPT. We now believe it’s having an impact on our new customer growth rate.”

Chegg expects second-quarter revenue to be in a range of $175 million to $178 million versus estimates of $193.64 million. The company sees subscription services revenues between $159 million and $162 million versus $168.4 million in the first quarter.

Following the print, Jefferies analyst Brent Thill downgraded Chegg from Buy to Hold and lowered the price target from $25 to $11. Piper Sandler analyst Arvind Ramnani maintained Chegg with a Neutral and lowered the price target from $17 to $11.

See Also: Tesla, SoFi, Chegg, JPMorgan, MicroStrategy: Why These 5 Stocks Are Drawing Investors’ Attention

CHGG Price Action: Chegg shares are making new 52-week lows on Tuesday.

The stock was down 44.5% at $9.76 at the time of publication, according to Benzinga Pro.

Photo: svklimkin from Pixabay.

Total
0
Shares
Related Posts
Read More

Annji Pharmaceutical Has Entered Into An Exclusive License Agreement With Avenue Therapeutics For AJ201 For Spinal And Bulbar Muscular Atrophy, Also Known As Kennedy’s Disease; Upfront Payment Of $3M, Milestone Payments Of Upto $250M

The deal covers the U.S., Canada, European Union, Great Britain, And Israel. Avenue will also issue 831,618 shares as equity upfront and additional shares upon the achievement of a clinical milestone, aggregating

ATXI